Safety and efficacy of aprepitant for chemotherapy-induced nausea and vomiting in pediatric patients: a prospective, observational study.

Megan Bodge, Alexandra Shillingburg, Stephan Paul, Lisa Biondo

Journal: Pediatric blood & cancer 2014;61(6):1111-3

PMID: 24357337

Full Text on Ovid Technologies, Inc. View on PubMed

Abstract

Pediatric patients between the ages of 12 months and 17 years with a confirmed malignancy who were scheduled to receive aprepitant as part of triple therapy antiemetic prophylaxis for a cycle of moderately- or highly emetogenic chemotherapy were eligible for enrollment. Patients were evaluated for the incidence of nausea, episodes of emesis, interference with activities of daily living (ADLs), and appetite through utilization of a patient survey. Eleven patients were enrolled for a total of 20 patient encounters, mean age 9.55 ± 4.85 (range, 12 months-17 years). Aprepitant was well-tolerated and complete response (CR) rate was 38.9%.

Address: Department of Pharmaceutical Services, Vanderbilt University Medical Center, Nashville, Tennessee.

DOI: 10.1002/pbc.24901

Link outs

Free resources

Medical:

https://medlineplus.gov/nauseaandvomiting.html

Other Literature Sources:

https://scite.ai/reports/24357337

Subscription / membership required

Full Text Sources:

MeSH Terms: Adolescent, Antiemetics, Antineoplastic Combined Chemotherapy Protocols, Aprepitant, Body Weight, Child, Child, Preschool, Dexamethasone, Drug Therapy, Combination, Female, Humans, Incidence, Infant, Male, Morpholines, Nausea, Neoplasms, Ondansetron, Prospective Studies, Remission Induction, Severity of Illness Index, Treatment Outcome, Vomiting